ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ITCI Intra Cellular Therapies Inc

66.53
-0.31 (-0.46%)
After Hours
Last Updated: 22:37:11
Delayed by 15 minutes
Share Name Share Symbol Market Type
Intra Cellular Therapies Inc NASDAQ:ITCI NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.31 -0.46% 66.53 67.00 67.56 67.095 65.51 66.72 723,533 22:37:11

The Klein Law Firm Announces a Class Action Filed on Behalf of Intra-Cellular Therapies, Inc. Shareholders & a Lead Plaintiff...

06/06/2017 4:45pm

Business Wire


Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Intra Cellular Therapies Charts.

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) who purchased shares between August 12, 2014 and April 28, 2017. The action, which was filed in the USDC for the Eastern District of New York, alleges that the Company violated federal securities laws.

In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (1) findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; (2) these findings posed an additional safety concern regarding lumateperone; (2) and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On August 4, 2016, the Company’s CEO Sharon Mates touted the “efficacy and safety of ITI-007 for the treatment of schizophrenia.” Then on May 1, 2017, Intra-Cellular disclosed that the U.S. Food and Drug Administration requested information from the Company in order to verify whether or not there are safety risks associated with long term exposure of ITI-007 to patients.

Shareholders have until July 11, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/intra-cellular-therapies-inc?wire=2.

Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

The Klein Law FirmJoseph Klein, Esq., 212-616-4899Fax: 347-558-9665www.kleinstocklaw.com

1 Year Intra Cellular Therapies Chart

1 Year Intra Cellular Therapies Chart

1 Month Intra Cellular Therapies Chart

1 Month Intra Cellular Therapies Chart

Your Recent History

Delayed Upgrade Clock